来氟米特联合甲氨蝶呤治疗类风湿性关节炎疗效分析

Efficacy Analysis of Leflunomide Combined with Methotrexate in the Treatment of Rheumatoid Arthritis

目的探讨来氟米特(LEF)联合甲氨蝶呤(MTX)治疗类风湿性关节炎的疗效.方法选取类风湿性关节炎患者70例,随机分为A组、B组,每组35例.A组采用来氟米特联合甲氨蝶呤治疗,B组采用甲氨蝶呤治疗,两组均连续治疗半年,比较两组患者的临床症状、炎症指标改善情况及不良反应发生率.结果治疗半年后,两组患者关节肿胀数、关节压痛数及晨僵持续时间较治疗前均改善,且A组关节肿胀、关节疼痛个数少于B组,晨僵时间A组短于B组(P<0.05);两组患者血沉(ESR)、C反应蛋白(CRP)及血清白介素-6(IL-6)较治疗前均改善,且A组较B组更低(P<0.05);A组治疗总有效率94.29%,高于B组的77.14%(P<0.05),两组患者并发症发生率组间比较差异无统计学意义(P>0.05).结论来氟米特联合甲氨蝶呤治疗类风湿性关节炎可明显改善患者的临床症状,与单用甲氨蝶呤相比临床疗效更显著,且不会增加不良反应,安全性高,值得临床推广.

Objective To investigate the efficacy of leflunomide(LEF)combined with methotrexate(MTX)in the treatment of rheumatoid arthritis.Method 70 patients with rheumatoid arthritis were randomly divided into group A and group B,with 35 cases in each group.Group A was treated with leflunomide combined with methotrexate,group B was treated with methotrexate,and both groups were treated continuously for half a year,comparing the improvement of clinical symptoms,inflammatory indexes and the incidence of adverse reactions between the two groups.Results After half a year of continuous treatment,the number of joint swelling,joint tenderness and duration of morning stiffness in both groups were improved,and the number of joint swellings and joint pain in group A were less than those in group B,morning stiffness time in group A was shorter than that in group B(P<0.05),serum erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)and serum interleukin-6(IL-6)improved in both groups comparing with those before treatment,and group A was lower than group B(P<0.05),the total effective rate of treatment in group A was 94.29%,which was higher than that in group B was 77.14%(P<0.05),there was no significant comparison of complication rates between the two groups(P>0.05).Conclusion Leflunomide combined with methotrexate in the treatment of rheumatoid arthritis can significantly improve the clinical symptoms of patients,and the clinical effect is more significant than that of methotrexate alone,and does not increase adverse reactions,and has high safety and is worthy of clinical promotion.